Hem › Övervikt › Arizona › Phoenix
Kliniska studier för Övervikt i Phoenix, AZ
15 studier för Övervikt söker deltagare vid platser i och runt Phoenix (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
RekryterarFas 3
- Absolute Clinical Research, Phoenix
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
RekryterarFas 3
- RIO Clinical Trials - Phoenix, Phoenix
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
RekryterarFas 3
- Research Site, Phoenix
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
RekryterarFas 3
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RekryterarFas 3
- Elite Clinical Studies, LLC, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
RekryterarFas 3
- AURORA-1 Clinical Site, Phoenix
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
RekryterarFas 3
- AURORA-2 Clinical Site, Phoenix
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RekryterarFas 2
- Helios Clinical Research - Phoenix, Phoenix
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
RekryterarFas 3Friska volontärer välkomna
- ACCOMPLISH-2 Research Site, Phoenix
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RekryterarFas 2
- Synexus Clinical Research US, Inc., Phoenix
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
RekryterarFas 4
- Medical Dermatology Specialists, Phoenix
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
RekryterarFas 3
- Kailera Clinical Site, Phoenix
Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
RekryterarObservationsstudie
- Exponent Phoenix, Phoenix
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
RekryterarFas 3
- ACCOMPLISH-1 Research Site, Phoenix
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RekryterarFas 3
- The University of Arizona College of Medicine- Phoenix, Phoenix
Övervikt-studier i andra städer
- San Antonio, TX34 studier
- Houston, TX33 studier
- Chicago, IL28 studier
- Orlando, FL27 studier
- Las Vegas, NV23 studier
- Miami, FL23 studier
- Atlanta, GA20 studier
- Dallas, TX20 studier
- New York City, NY19 studier
- Jacksonville, FL19 studier
- Washington, DC19 studier
- Austin, TX18 studier
Andra studier i Phoenix
- Bröstcancer25 studier
- Kolorektal cancer25 studier
- Övervikt22 studier
- Icke-småcellig lungcancer20 studier
- Metastaserande cancer20 studier
- Hjärtsvikt18 studier
- Prostatacancer17 studier
- Cancer (alla typer)17 studier
- Multipelt myelom16 studier
- Bukspottkörtelcancer16 studier
- Hjärt-kärlsjukdom16 studier
- Alzheimers sjukdom15 studier
Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.